CXADR Antibody (Med. Bio. Labs patent anti-CXADR) [DyLight 350]
Novus Biologicals, part of Bio-Techne | Catalog # NBP3-28411UV
Recombinant Monoclonal Antibody
Conjugate
Catalog #
Key Product Details
Species Reactivity
Human
Applications
ELISA, Flow Cytometry, Functional
Label
DyLight 350 (Excitation = 353 nm, Emission = 432 nm)
Antibody Source
Recombinant Monoclonal Human IgG2 Clone # Med. Bio. Labs patent anti-CXADR
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Product Specifications
Immunogen
CXADR
Clonality
Monoclonal
Host
Human
Isotype
IgG2
Applications for CXADR Antibody (Med. Bio. Labs patent anti-CXADR) [DyLight 350]
Application
Recommended Usage
ELISA
Optimal dilutions of this antibody should be experimentally determined.
Flow Cytometry
Optimal dilutions of this antibody should be experimentally determined.
Functional
Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Protein A purified
Formulation
50mM Sodium Borate
Preservative
0.05% Sodium Azide
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C in the dark.
Background: CXADR
Long Name
Coxsackie and Adenovirus Receptor
Alternate Names
CVB3 BP
Gene Symbol
CXADR
Additional CXADR Products
Product Documents for CXADR Antibody (Med. Bio. Labs patent anti-CXADR) [DyLight 350]
Product Specific Notices for CXADR Antibody (Med. Bio. Labs patent anti-CXADR) [DyLight 350]
DyLight (R) is a trademark of Thermo Fisher Scientific Inc. and its subsidiaries.
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...